Video

SUO 2024 VL

Expanded Access Program Provides Early Cretostimogene Therapy for Bladder Cancer - Sarah Psutka Details Sarah Psutka examines the expanded access program (EAP) for cretostimogene in BCG-unresponsive bladder cancer. The conversation highlights how this oncolytic immunotherapy, which shows a 74% complete response rate and strong durability, is being made available through an EAP designed to gather real-world data from diverse patient populations. Dr. Psutka emphasizes the program's broad eligibility c...
Utilizing Telehealth to Improve Access of Care of Patients with Bladder Cancer - Tracey Krupski Details Tracey Krupski explores the implementation of tele-cystoscopy to improve access to bladder cancer care in resource-challenged areas. Dr. Krupski shares research demonstrating how trained advanced practice providers can perform remote cystoscopies while urologists supervise via video connection, significantly reducing travel burden for patients in underserved regions. The study validates the approa...
Integrating Genomic Testing with MRI Enhances Stratification of Surveillance Patients - Eric Kim & Mark Sultan Details Mark Sultan and Eric Kim discuss research on predicting prostate cancer progression during active surveillance using Decipher® genomic classifier scores and MRI characteristics. Their study reveals that while both high Decipher® scores and high-risk MRI findings independently predict progression, these markers are weakly correlated, suggesting they capture distinct risk information. The conversati...
Current Options for BCG Unresponsive NMIBC in 2024 - Eugene Pietzak Details Sam Chang hosts Eugene Pietzak to discuss treatment options for BCG-unresponsive bladder cancer and the challenges of evaluating their comparative effectiveness. Dr. Pietzak emphasizes that while multiple FDA-approved treatments are now available, including pembrolizumab, nadofaragene, and BCG with IL-15 superagonist, comparing their efficacy is complicated by variations in trial designs, surgeon...
Emerging Neoadjuvant Combinations for Muscle-Invasive Bladder Cancer - Mamta Parikh Details Mamta Parikh explores emerging combination therapies for muscle-invasive bladder cancer. Dr. Parikh details several ongoing trials evaluating various treatment combinations, including checkpoint inhibitors with chemotherapy, antibody-drug conjugates, and intravesical therapies in both cisplatin-eligible and ineligible patients. The conversation highlights the practice-changing potential of the NIA...
PIVOT-006: Phase III Trial of Creto vs Surveillance in Intermediate-Risk Bladder Cancer - Mark Tyson Details A discussion between Zachary Klaassen and Mark Tyson explores the PIVOT-006 trial examining cretostimogene versus surveillance for intermediate-risk non-muscle invasive bladder cancer. The study evaluates this oncolytic immunotherapy in a new patient population, focusing on both low-grade and high-grade disease that meets specific AUA criteria for intermediate risk. The trial design includes an in...
BCG Unresponsive Bladder Cancer in 2024 - Ashish Kamat Details Zachary Klaassen and Ashish Kamat explore the evolving landscape of BCG-unresponsive bladder cancer treatment. Dr. Kamat traces the development of treatment options from the establishment of BCG-unresponsive disease criteria to the current array of approved and emerging therapies, including pembrolizumab, nadofaragene, and newer agents like TAR-200 and cretostimogene. The discussion emphasizes the...
BOND-003 Trial Results in BCG Unresponsive Non-muscle Invasive Bladder Cancer - Mark Tyson Details Zachary Klaassen hosts Mark Tyson to discuss the BOND-003 trial evaluating cretostimogene for BCG-unresponsive NMIBC. This study examines the mechanism by which this oncolytic immunotherapy selectively targets cancer cells by exploiting Rb pathway deficiencies and enhancing tumor-specific immunity through GM-CSF expression. The discussion highlights the treatment's promising efficacy with high com...

SUO 2024 VL

Login